Author: Siggi Trier (United Kingdom)
Co-authors: Pakinam Aboulsaoud, Juliette Vandenbroucque, Federico Ricci, Charlies C. Wykoff
Purpose
To aid early adoption of new therapies for nAMD and DME and optimize treatment selection, ophthalmologists (Opht) can benefit from continued access to unbiased medical information and expert guidance to better understand new mechanisms of action, and their impact on clinical parameters to evaluate clinical data from emerging treatments against the standard of care. The purpose of the study was to determine if online medical education could increase familiarity with the Angiopoeitin/Tie pathway, the clinical impact of angiopoeitin-2 (Ang-2)- inhibition in retinal diseases and pivotal data recall for emerging bispecific (anti-VEGF, anti-Ang-2) antibody faricimab in retinal diseases, compared to ranibizumab.
Setting/Venue
Leading members only website providing access to medical information for clinicians as well as independent accredited continuing medical education for physicians and health professionals, including a dedicated ophthalmology section
Methods
Participants completed a 3-item questionnaire plus a confidence assessment before and after watching a 15-minute expert peer-to-peer discussion with accompanying slides. A matched pair design was used pre-/post-assessment, with scores compared to assess changes in the proportion of correct responses. A chi-squared test assessed statistical significance at the p<.05 level. Confidence levels assessed on a 5-point-Likert scale. Launch Aug 27, 2020; data through Nov 19, 2020. Assessment completers: 136, target audience: 666 learners
Results
An average of 56% of Opht responses on pre-assessment were correct, increasing to 72% on post-assessment (p<.001). The activity confirmed a high baseline knowledge of the role of Ang-2 for retinal vascular stability (pre: 76%, post: 79%). Nevertheless 60% of learners had a measurable improvement in confidence describing the Angiopoeitin/Tie pathway with 64% placing themselves in the 3 higher confidence levels after watching the program, increasing from 28% in pre-assessment. Knowledge on faricimab’s performance versus ranibizumab significantly increased on durability aspects in the nAMD Stairway trial (pre: 40%, post: 68%, p<.001) and anatomical results in the DME Boulevard trial (pre: 51%, post: 68%, p =.0066). 88% of Opht polled saw a need for new treatments in retinal disease.
Conlusions
Online medical education is a fast and effective method for successful dissemination of clinical trial results for emerging therapies in retinal diseases to ophthalmologists and can boost confidence in understanding novel pathways, even in the presence of high baseline knowledge. This 15-minute online expert video discussion with synchronized slides produced highly significant improvements on factual recall of pivotal clinical trial results for the emerging bispecific (anti-VEGF, anti-Ang-2) antibody faricimab for treatment of nAMD and DME and increased familiarity with the underlying mechanism of action. The educational activity was of high relevance to Ophth due to the need for new treatments in retinal diseases.
Financial Disclosure
Siggi Trier is a Consultant for Medscape LLC. Pakinam Aboulsaoud and Juliette Vandenbroucque are Employees of Medscape. Federico Ricci served as an advisor or consultant for: Alimera; Allergan; Bayer; Formicon; Genentech; MS&D; Novartis; Regeneron; Roche and received grants for clinical research from: Allergan; Bayer; Novartis. Charles C. Wykoff has disclosed no relevant financial relationships The educational program for this outcomes study was developed through an independent educational grant from Roche to Medscape.
Comments
-